 |
 |

The Placebo Problem Remains
Arch Gen Psychiatry. 2000;57:321-322.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
NEW MEDICINES for which a manufacturer seeks market approval are usually tested against placebo, irrespective of whether effective treatment already exists for the condition. This is a requirement set forth by the US Food and Drug Administration (FDA).1 The FDA maintains that placebo-controlled trials are necessary for an easy comparison of the new drug with "nothing," whereas evaluating therapeutic equivalence of a new vs an old medication is more problematic.2 Many patients in clinical trials are therefore deprived of effective medications. A few years ago, my colleague Ken Rothman and I drew attention to this unethical use of placebo controls.3 If effective therapy exists, the physician has an ethical and legal obligation to provide it to the patient according to ethical standards that are laid out in the Declaration of Helsinki.4 The Declaration of Helsinki mandates that a new drug be compared with the best available treatment, thus placing the . . . [Full Text of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Ethical aspects of placebo groups in pain trials: Lessons from psychiatry
Nagasako and Kalauokalani
Neurology 2005;65:S59-S65.
ABSTRACT
| FULL TEXT
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh et al.
JAMA 2002;287:1840-1847.
ABSTRACT
| FULL TEXT
The Undiscovered Mind: How the Human Brain Defies Replication, Medication, and Explanation
FORREST
Am. J. Psychiatry 2002;159:333-334.
FULL TEXT
Pharmacologic Treatment of Traumatized Children
COHEN
Trauma Violence Abuse 2001;2:155-171.
ABSTRACT
|